Indaptus Therapeutics Inc

Change company Symbol lookup

Select an option...

INDP Indaptus Therapeutics Inc

SCHL Scholastic Corp

SIDU Sidus Space Inc

MGY Magnolia Oil & Gas Corp

CWBR CohBar Inc

UPTDU TradeUP Acquisition Corp

BHAC Crixus BH3 Acquisition Co

ASPA Abri SPAC I Inc

WORX Scworx Corp

WY Weyerhaeuser Co

Go

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.